摘要
目的观察曲伏前列素与噻吗洛尔滴眼液治疗老年青光眼临床疗效与安全性差异,优化青光眼治疗方案。方法将88例青光眼患者分为曲伏前列素组44例(80眼)与噻吗洛尔组44例(76眼),分别滴用曲伏前列素与噻吗洛尔滴眼液,治疗4周,观察治疗前后眼压、昼夜眼压差、视野缺损,记录不良反应发生情况。结果 (1)曲伏前列素、噻吗洛尔治疗后平均眼压、昼夜眼压差、视野缺损均较治疗前明显降低(P<0.01或P<0.05),治疗后曲伏前列素组与噻吗洛尔组平均眼压、昼夜眼压差、视野缺损、平均眼压下降值分别为(19.23±2.43)比(23.28±3.54),(4.03±0.78)比(5.54±0.86),(6.82±0.34)比(8.03±0.83),(8.25±1.31)比(5.27±0.86),曲伏前列素组平均眼压、昼夜眼压差、视野缺损均较对照组明显降低,平均眼压下降值较对照组明显升高(均P<0.05);(2)曲伏前列素组和噻吗洛尔组不良反应发生率分别为20%(16/80)和18.42%(14/76),两组不良反应差异无统计学意义(x2=0.063,P>0.05)。结论曲伏前列素滴眼液是治疗老年青光眼强效、稳定和安全的药物,可作为临床老年各类青光眼的首选治疗药物。
Objective To observe the clinical efficacy and safety of travoprost and timolol eye drops in the treatment of elderly glaucoma,and to optimize the treatment program of glaucoma. Methods 88 glaucoma patients were randomly divided into 44 cases of the travoprost group （80 eyes） and 44 cases of timolol group （76 eyes）,and were respectively given travoprost and timolol eye drops,observed intraocular pressure,IOP,visual field defects before and after treatment,and recorded the occurrence of adverse reactions. Results （1）the intraocular pressure,IOP,visual field defects of travoprost and timolol after treatment were significantly lower than before treatment（P 〈 0.01 or P 〈 0.05）,the intraocular pressure,IOP,visual field defects of travoprost and timolol,IOP decreased value after treatment were （19.23 ± 2.43） vs （23.28 ± 3.54）,（4.03 ± 0.78） vs （5.54 ± 0.86）,（6.82 ± 0.34） vs （8.03 ± 0.83）,（8.25 ± 1.31） vs （5.27 ± 0.86）,the intraocular pressure,IOP,visual field defects of travoprost and timolol of travoprost group were significantly lower than the timolol group,the IOP decreased value of travoprost group were significantly higher than the timolol group,all （P 〈 0.05）;（2）The adverse incidence of travoprost group and timolol group were 20% （16/80） and 18.42%（14/76）,there were no statistically significant difference between two groups（x2=0.063 ,P ± 0.05）. Conclusion Travoprost eye drops is powerful,stability and security of drugs in treatment of elderly glaucoma,can be as the preferred treatment of drug in the treatment of various types of elderly glaucoma.
出处
《中国医药科学》
2013年第7期100-101,105,共3页
China Medicine And Pharmacy
